The University of Iowa Tissue Culture Hybridoma Core is a shared resource available to all members of the UICC. It has been in operation since 1982 and was used by 62 UICC members over the past year. The Facility specializes in tissue culture services, and also supplies both tissue culture and molecular biology reagents. Tissue culture services provided by the Facility include production of hybridomas, cloning of cell lines, and generation of mAb containing supernatants. These are provided on a time and material basis, resulting in substantial saving for investigators. Tissue culture reagents include tissue culture media (both vendor supplied and custom-made media), sera, antibiotics, transfection reagents and other medium supplements. Molecular biology supplies encompass a large panel of DNA restriction, endonucleases, in addition to reagents for DNA and RNA purification, RNAse protection assays, PCR, sequencing, and cloning. Both tissue culture and molecular biology supplies are offered at reduced cost (below vendor prices) since the Tissue Culture/Hybridoma Facility purchases these products in bulk quantities at a volume discount. This latter service is not only a major convenience to investigators, but allows for further savings as waste is minimized. Collectively, the University of Iowa Culture/Hybridoma Facility has become a major resource for Cancer Center investigators in cell biology, molecular biology, immunology, and oncology research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
1P30CA086862-01
Application #
6401911
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2000-07-14
Project End
2005-06-30
Budget Start
Budget End
Support Year
1
Fiscal Year
2000
Total Cost
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
041294109
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Brooks, Jennifer D; Comen, Elizabeth A; Reiner, Anne S et al. (2018) CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study. Breast Cancer Res 20:149
Chioreso, Catherine; Del Vecchio, Natalie; Schweizer, Marin L et al. (2018) Association Between Hospital and Surgeon Volume and Rectal Cancer Surgery Outcomes in Patients With Rectal Cancer Treated Since 2000: Systematic Literature Review and Meta-analysis. Dis Colon Rectum 61:1320-1332
Musselman, Catherine A; Kutateladze, Tatiana G (2018) A histone reader becomes the readout. J Biol Chem 293:7486-7487
Merritt, Nicole M; Fullenkamp, Colleen A; Hall, Sarah L et al. (2018) A comprehensive evaluation of Hippo pathway silencing in sarcomas. Oncotarget 9:31620-31636
Haskins, Cole B; McDowell, Bradley D; Carnahan, Ryan M et al. (2018) Impact of preexisting mental illness on breast cancer endocrine therapy adherence. Breast Cancer Res Treat :
Daneshmand, Siamak; Patel, Sanjay; Lotan, Yair et al. (2018) Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. J Urol 199:1158-1165
Kim, Yusung; Cabel, Katherine; Sun, Wenqing (2018) Does the apex optimization line matter for single-channel vaginal cylinder brachytherapy planning? J Appl Clin Med Phys 19:307-312
Hagan, Teresa L; Gilbertson-White, Stephanie; Cohen, Susan M et al. (2018) Symptom Burden and Self-Advocacy: Exploring the Relationship Among Female Cancer Survivors?. Clin J Oncol Nurs 22:E23-E30
Chesney, Jason; Puzanov, Igor; Collichio, Frances et al. (2018) Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol 36:1658-1667
Kleinstern, Geffen; Maurer, Matthew J; Liebow, Mark et al. (2018) History of autoimmune conditions and lymphoma prognosis. Blood Cancer J 8:73

Showing the most recent 10 out of 1080 publications